A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management

NCT02078492 ↗

Phase 4 Completed 240 enrolled Antonios Likourezos

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.

Timeline

Start: 2014-03
Primary completion: 2015-12
Completion: 2015-12

Publications

Background Catapano MS. The analgesic efficacy of ketorolac for acute pain. J Emerg Med. 1996 Jan-Feb;14(1):67-75. doi: 10.1016/0736-4679(95)02052-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketorolac	Other / unclassified	10 mg	Intravenous
Subject	Ketorolac	Other / unclassified	15 mg	Intravenous
Subject	Ketorolac	Other / unclassified	30 mg	Intravenous

Indications

No indication recorded.